Avantax Advisory Services Inc. Acquires New Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Avantax Advisory Services Inc. acquired a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 10,973 shares of the company’s stock, valued at approximately $145,000.

Several other hedge funds have also recently bought and sold shares of TAK. FMR LLC boosted its stake in shares of Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after acquiring an additional 286,052 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Takeda Pharmaceutical by 1.6% in the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after purchasing an additional 35,192 shares during the last quarter. Stifel Financial Corp boosted its position in Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares during the period. Quantinno Capital Management LP grew its holdings in Takeda Pharmaceutical by 2.9% during the third quarter. Quantinno Capital Management LP now owns 361,713 shares of the company’s stock valued at $5,144,000 after purchasing an additional 10,258 shares during the last quarter. Finally, QRG Capital Management Inc. raised its position in shares of Takeda Pharmaceutical by 16.8% in the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock valued at $4,364,000 after purchasing an additional 47,490 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $15.15 on Friday. The company has a market cap of $48.19 billion, a P/E ratio of 37.86, a P/E/G ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.31. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $14.12 and a 200 day simple moving average of $13.93.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.